Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151099 | 0.97 | MAPT (0.51) | MAPTRXFP1LMNAPDK1THRB | |
| SCHEMBL7150052 | 0.95 | PDK1 (0.51) | MAPTRXFP1LMNAPDK1POLB | |
| SCHEMBL7149325 | 0.94 | MAPT (0.53) | MAPTRXFP1LMNAPDK1THRB | |
| SCHEMBL7146179 | 0.92 | PDK1 (0.50) | MAPTRXFP1LMNAPDK1TP53 | |
| SCHEMBL7143828 | 0.90 | MAPT (0.46) | MAPTRXFP1LMNAPDK1THRB | |
| SCHEMBL7153222 | 0.89 | PDK1 (0.53) | MAPTRXFP1LMNAPDK1TP53 | |
| SCHEMBL7148790 | 0.88 | MAPT (0.50) | MAPTLMNAPDK1THRBTP53 | |
| SCHEMBL7147692 | 0.88 | MAPT (0.44) | MAPTRXFP1LMNATHRBTP53 | |
| SCHEMBL7149250 | 0.88 | PDK1 (0.52) | MAPTRXFP1LMNAPDK1THRB | |
| SCHEMBL7149832 | 0.87 | MAPT (0.45) | MAPTRXFP1LMNAPDK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642263-B2 | Antitumor agents, sulfided benzothiazole derivative containing sulfonamide | ICONIX PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030176474-A1 | Modulators of Rho C activity | ICONIX BIOSCIENCES, INC. | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176474-A1 | Modulators of Rho C activity | RHOC, ARHGDIA, ROCK1 | MAPT 3839/4885RXFP1 667/4885LMNA 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.